Every DEF 14A that GeoVax Labs, Inc. New (GOVX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow GOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVX filings page.
GeoVax Labs, Inc. (GOVX) has called a special stockholder meeting on October 27, 2026 to vote on two key proposals. The first seeks approval to issue up to 11,395,256 shares of common stock upon exercise of an August 2026 warrant with a $0.64 per-share exercise price, in order to comply with Nasdaq Listing Rules 5635(b) and 5635(d) and potentially raise up to $7.29 million in gross proceeds. These shares would represent about 55.6% of common stock on a post‑exercise basis, though a 4.99% blocker limits the warrant holder’s beneficial ownership at any time.
The second proposal would authorize the Board, at its discretion, to implement a reverse stock split of the outstanding common stock at a ratio between 1‑for‑10 and 1‑for‑25 to help regain compliance with Nasdaq’s $1.00 minimum bid requirement after receiving a Nasdaq staff determination to delist following a prior 1‑for‑30 reverse split in January 2026. There were 9,093,871 shares outstanding as of August 28, 2026; the reverse split would reduce the share count proportionally without changing each holder’s percentage ownership, and may involve cash or rounding up for fractional shares at the Board’s discretion.
GeoVax Labs, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on June 17, 2026 and asks holders to vote on director elections and seven proposals, including stockholder approval to issue shares upon exercise of warrants issued in February, March and May 2026.
The proxy materials fix April 20, 2026 as the record date; as disclosed, there were 2,892,570 shares outstanding as of April 20, 2026. The Board recommends votes FOR election of seven director nominees and FOR the issuance of shares upon exercise of the February 2026, March 2026 and May 2026 warrants, ratification of the independent auditor, and advisory votes on executive compensation.
GeoVax Labs, Inc. is calling a June 17, 2026 annual stockholder meeting in Atlanta to elect seven directors, approve two key warrant-exercise share issuances, ratify its independent auditor, and hold advisory votes on executive pay and the future frequency of say‑on‑pay votes.
The proxy details board structure, director and executive biographies, compensation, equity plans, and large 2025–2026 capital raises using common stock, pre‑funded warrants, and common warrants, including new February and March 2026 warrant structures that require stockholder approval before full exercise.